Results 221 to 230 of about 140,144 (311)

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

Rare Invasive Fusarium Sinusitis in a Transiently Immunosuppressed Patient. [PDF]

Cureus
Archibald VL, Meenrajan SR, Schain D, Tishena A, Lo MC.   +4 more
europepmc   +1 more source

Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025

British Journal of Haematology, EarlyView.
K. Tozatto‐Maio, V. Weihermann, C. W. Erthal, M. W. Araújo, C. R. Gomes, K. Caciola, L. Otuyama, J. Gasparini, H. R. Higashino, S. F. Costa, A. N. Duarte‐Neto, F. S. Seguro, P. R. Villaça, E. D. R. P. Velloso, S. F. M. Gualandro, Y. Nukui, V. Rocha   +16 more
wiley   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka   +9 more
wiley   +1 more source

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. [PDF]

Oncol Res
Zhong G, Yang T, Lin S, Zhong M.
europepmc   +1 more source

[Febrile neutropenia].

Nihon rinsho. Japanese journal of clinical medicine, 2013
openaire   +3 more sources

Retreatment with talquetamab and pomalidomide in triple‐class–BCMA–GPRC5D refractory myeloma

British Journal of Haematology, EarlyView.
Kian J. Rahbari, Gliceida M. Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W. Sborov, Muhamed Baljevic   +4 more
wiley   +1 more source

Autoimmune myelofibrosis with a <i>TLR8</i> gain-of-function defect. [PDF]

Leuk Res Rep
Qu S, Zhang P, Xu Z, Qin T, Li B, Xiao Z.   +5 more
europepmc   +1 more source

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source